Purnima Singh1, Xuexia Wang2, Lindsey Hageman1, Yanjun Chen1, Tarek Magdy3, Wendy Landier1, Jill P Ginsberg4, Joseph P Neglia5, Charles A Sklar6, Sharon M Castellino7, Zoann E Dreyer8, Melissa M Hudson9, Leslie L Robison9, Javier G Blanco10, Mary V Relling11, Paul Burridge3, Smita Bhatia1. 1. Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama, USA. 2. Department of Mathematics, University of North Texas, Denton, Texas, USA. 3. Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. 4. Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 5. Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA. 6. Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. 7. Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia, USA. 8. Department of Pediatrics, Texas Children's Cancer Center, Houston, Texas, USA. 9. Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, Tennessee, USA. 10. Department of Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo, New York, USA. 11. Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Abstract
BACKGROUND: Anthracycline-related cardiomyopathy is a leading cause of late morbidity in childhood cancer survivors. Glutathione S-transferases (GSTs) are a class of phase II detoxification enzymes that facilitate the elimination of anthracyclines. As free-radical scavengers, GSTs could play a role in oxidative damage-induced cardiomyopathy. Associations between the GSTμ1 (GSTM1) null genotype and iron-overload-related cardiomyopathy have been reported in patients with thalassemia. METHODS: The authors sought to identify an association between the GSTM1 null genotype and anthracycline-related cardiomyopathy in childhood cancer survivors and to corroborate the association by examining GSTM1 gene expression in peripheral blood and human-induced pluripotent stem cell cardiomyocytes (hiPSC-CMs) from survivors with and without cardiomyopathy. GSTM1 gene deletion was examined by polymerase chain reaction in 75 survivors who had clinically validated cardiomyopathy (cases) and in 92 matched survivors without cardiomyopathy (controls). Conditional logistic regression analysis adjusting for sex, age at cancer diagnosis, chest radiation, and anthracycline dose was used to assess the association between genotype and cardiomyopathy. Proprietary bead array technology and quantitative real-time polymerase chain reaction were used to measure GSTM1 expression levels in samples from 20 cases and 20 matched controls. hiPSC-CMs from childhood cancer survivors (3 with cardiomyopathy, 3 without cardiomyopathy) also were examined for GSTM1 gene expression levels. RESULTS: A significant association was observed between the risk of cardiomyopathy and the GSTM1 null genotype (odds ratio, 2.7; 95% CI, 1.3-5.9; P = .007). There was significant downregulation of GSTM1 expression in cases compared with controls (average relative expression, 0.67 ± 0.57 vs 1.33 ± 1.33, respectively; P = .049). hiPSC-CMs from patients who had cardiomyopathy revealed reduced GSTM1 expression (P = .007). CONCLUSIONS: The current findings could facilitate the identification of childhood cancer survivors who are at risk for anthracycline-related cardiomyopathy.
BACKGROUND:Anthracycline-related cardiomyopathy is a leading cause of late morbidity in childhood cancer survivors. Glutathione S-transferases (GSTs) are a class of phase II detoxification enzymes that facilitate the elimination of anthracyclines. As free-radical scavengers, GSTs could play a role in oxidative damage-induced cardiomyopathy. Associations between the GSTμ1 (GSTM1) null genotype and iron-overload-related cardiomyopathy have been reported in patients with thalassemia. METHODS: The authors sought to identify an association between the GSTM1 null genotype and anthracycline-related cardiomyopathy in childhood cancer survivors and to corroborate the association by examining GSTM1 gene expression in peripheral blood and human-induced pluripotent stem cell cardiomyocytes (hiPSC-CMs) from survivors with and without cardiomyopathy. GSTM1 gene deletion was examined by polymerase chain reaction in 75 survivors who had clinically validated cardiomyopathy (cases) and in 92 matched survivors without cardiomyopathy (controls). Conditional logistic regression analysis adjusting for sex, age at cancer diagnosis, chest radiation, and anthracycline dose was used to assess the association between genotype and cardiomyopathy. Proprietary bead array technology and quantitative real-time polymerase chain reaction were used to measure GSTM1 expression levels in samples from 20 cases and 20 matched controls. hiPSC-CMs from childhood cancer survivors (3 with cardiomyopathy, 3 without cardiomyopathy) also were examined for GSTM1 gene expression levels. RESULTS: A significant association was observed between the risk of cardiomyopathy and the GSTM1 null genotype (odds ratio, 2.7; 95% CI, 1.3-5.9; P = .007). There was significant downregulation of GSTM1 expression in cases compared with controls (average relative expression, 0.67 ± 0.57 vs 1.33 ± 1.33, respectively; P = .049). hiPSC-CMs from patients who had cardiomyopathy revealed reduced GSTM1 expression (P = .007). CONCLUSIONS: The current findings could facilitate the identification of childhood cancer survivors who are at risk for anthracycline-related cardiomyopathy.
Authors: G M Felker; R E Thompson; J M Hare; R H Hruban; D E Clemetson; D L Howard; K L Baughman; E K Kasper Journal: N Engl J Med Date: 2000-04-13 Impact factor: 91.245
Authors: Daniel L Hertz; Megan V Caram; Kelley M Kidwell; Jacklyn N Thibert; Christina Gersch; Nicholas J Seewald; Jeffrey Smerage; Melvyn Rubenfire; N Lynn Henry; Kathleen A Cooney; Monika Leja; Jennifer J Griggs; James M Rae Journal: Pharmacogenomics Date: 2016-01-22 Impact factor: 2.533
Authors: M Krajinovic; J Elbared; S Drouin; L Bertout; A Rezgui; M Ansari; M-J Raboisson; S E Lipshultz; L B Silverman; S E Sallan; D S Neuberg; J L Kutok; C Laverdière; D Sinnett; G Andelfinger Journal: Pharmacogenomics J Date: 2015-09-08 Impact factor: 3.550
Authors: María Santos; Mikko Niemi; Masahiro Hiratsuka; Masaki Kumondai; Magnus Ingelman-Sundberg; Volker M Lauschke; Cristina Rodríguez-Antona Journal: Genet Med Date: 2017-10-26 Impact factor: 8.822
Authors: Folefac Aminkeng; Amit P Bhavsar; Henk Visscher; Shahrad R Rassekh; Yuling Li; Jong W Lee; Liam R Brunham; Huib N Caron; Elvira C van Dalen; Leontien C Kremer; Helena J van der Pal; Ursula Amstutz; Michael J Rieder; Daniel Bernstein; Bruce C Carleton; Michael R Hayden; Colin J D Ross Journal: Nat Genet Date: 2015-08-03 Impact factor: 38.330
Authors: Eric J Chow; Lena E Winestone; Philip J Lupo; Lisa R Diller; Tara O Henderson; Nina S Kadan-Lottick; Jennifer M Levine; Kirsten K Ness; Smita Bhatia; Saro H Armenian Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-09-02 Impact factor: 4.090
Authors: Nicolas Waespe; Sven Strebel; Tiago Nava; Chakradhara Rao S Uppugunduri; Denis Marino; Veneranda Mattiello; Maria Otth; Fabienne Gumy-Pause; André O Von Bueren; Frederic Baleydier; Luzius Mader; Adrian Spoerri; Claudia E Kuehni; Marc Ansari Journal: BMJ Open Date: 2022-01-24 Impact factor: 2.692